18,315 Shares in CRISPR Therapeutics AG $CRSP Acquired by Nwam LLC

Nwam LLC bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 18,315 shares of the company’s stock, valued at approximately $891,000.

A number of other large investors also recently made changes to their positions in the business. SVB Wealth LLC acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth $25,000. Costello Asset Management INC purchased a new position in CRISPR Therapeutics during the first quarter worth about $27,000. Atlantic Union Bankshares Corp acquired a new stake in CRISPR Therapeutics in the 2nd quarter worth about $33,000. Quantbot Technologies LP boosted its stake in CRISPR Therapeutics by 272.4% in the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock worth $45,000 after buying an additional 978 shares during the last quarter. Finally, IFP Advisors Inc grew its holdings in CRISPR Therapeutics by 24.6% in the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after buying an additional 181 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 1,076 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $67.91, for a total value of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares in the company, valued at $17,262,789.91. This trade represents a 16.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 56,213 shares of company stock valued at $3,810,458. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Up 1.2%

Shares of CRSP stock opened at $55.21 on Wednesday. The company has a market cap of $5.02 billion, a PE ratio of -9.88 and a beta of 1.89. The company’s fifty day simple moving average is $63.03 and its 200-day simple moving average is $53.45. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.49% and a negative net margin of 1,273.70%.The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $8.74 million. Equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on CRSP. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Needham & Company LLC decreased their price target on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating on the stock in a report on Monday. Barclays upped their price objective on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Zacks Research raised CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Finally, Royal Bank Of Canada boosted their price target on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average target price of $68.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.